Source disclosure: February 26, 2026, 15:30 JST
WAKAMOTO PHARMACEUTICAL CO.,LTD. [4512.T]
TOKYO, Feb 26 (Pulse News Wire) -- Wakamoto Pharmaceutical Co., Ltd. (4512.T), announced today that it has decided to appoint a new representative director as part of its ongoing strategic leadership transition. The company's board of directors, which met on February 26, 2026, resolved to make changes to the roles of its top executives to ensure continued growth and enhanced corporate value moving forward.
The current president and CEO, Igarashi Aritaka, will assume the position of chairman of the board, while Hiroyuki Hiraï will take over as the new representative director. This decision comes after two years since the launch of the mid-term business plan aimed at achieving goals by fiscal year 2028, during which time the company has made significant progress towards its targets.
Hiroyuki Hiraï, born on October 9, 1965, is set to become the new representative director starting April 1, 2026. He currently holds 5,000 shares of the company stock as of September 30, 2025. Prior to joining Wakamoto Pharmaceutical, Hiraï had an extensive career in finance and management. He graduated from Keio University’s Faculty of Economics in March 1989 and began his career at Nippon Credit Bank (now Mizuho Financial Group). Over the course of his career, he held various senior positions including deputy head of the Asset Management Division at Mizuhobank Corporate Bank, vice-president of the Public Finance Department at Mizoho Securities, and director at Western Oil Corporation. Hiraï joined Wakamoto Pharmaceutical as a councilor in April 2023 and was promoted to executive director in June 2024.
This change in leadership reflects the company's commitment to maintaining momentum in its strategic initiatives and ensuring sustainable development in the pharmaceutical industry. The move is expected to further strengthen the company's governance structure and drive future success.
The company disclosed details regarding changes to its board and executive management. For full details, please refer to the original disclosure document.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing